scispace - formally typeset
F

Flaviano Giorgini

Researcher at University of Leicester

Publications -  92
Citations -  9928

Flaviano Giorgini is an academic researcher from University of Leicester. The author has contributed to research in topics: Neurodegeneration & Kynurenine pathway. The author has an hindex of 38, co-authored 86 publications receiving 8742 citations. Previous affiliations of Flaviano Giorgini include University of Washington.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration.

Daniel Zwilling, +24 more
- 10 Jun 2011 - 
TL;DR: Chronic oral administration of JM6 inhibits KMO in the blood, increasing kynurenic acid levels and reducing extracellular glutamate in the brain, and it extends life span, prevents synaptic loss, and decreases microglial activation in a mouse model of Huntington's disease.
Journal ArticleDOI

A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease.

Flaviano Giorgini, +4 more
- 03 Apr 2005 - 
TL;DR: A genome-wide loss-of-function suppressor screen is reported in which 28 gene deletions that suppress toxicity of a mutant Htt fragment are identified, suggestive of a conserved mechanism of polyglutamine toxicity from yeast to humans and identifies new candidate therapeutic targets for the treatment of Huntington disease.
Journal ArticleDOI

The Kynurenine Pathway Modulates Neurodegeneration in a Drosophila Model of Huntington's Disease

Susanna Campesan, +7 more
- 07 Jun 2011 - 
TL;DR: This study provides the first genetic evidence that inhibition of KMO and TDO activity protects against neurodegenerative disease in an animal model, indicating that strategies targeted at two key points within the KP may have therapeutic relevance in HD, and possibly other neuro degenerative disorders.
Journal ArticleDOI

The kynurenine pathway and neurodegenerative disease.

Daniel C. Maddison, +1 more
- 01 Apr 2015 - 
TL;DR: An overview of the kynurenine pathway, its role in neurodegeneration and the current strategies for therapeutic targeting of the pathway can be found in this article, where a number of the pathways metabolites are neuroactive; e.g. can modulate activity of several glutamate receptors and generate/scavenge free radicals.